PharVision Advisers’s CBRE Group CBRE Stock Holding History

PharVision Advisers’s Portfolio CBRE Stock Details CBRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,351	Closed	-$217K	–	187
2025 Q4	$217K	Sell	1,351 -49	-4%	-$7.7K	0.11%	491
2025 Q3	$221K	Buy	+1,400	New	+$217K	0.12%	426

Other funds holding CBRE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PharVision Advisers's CBRE Position: Q1 2026 in Review

PharVision Advisers sold out of CBRE Group (CBRE) in Q1 2026, closing a stake of 1,351 shares — an estimated $217K sold.

PharVision Advisers first reported a position in CBRE in Q3 2025 and held it in 2 quarters. The position peaked at $221K in Q3 2025. 1,074 funds tracked by Wall St. Rank hold CBRE as of Q1 2026.

PharVision Advisers reported no remaining CBRE Group position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,351 CBRE Group shares in Q1 2026, an estimated $217K.
PharVision Advisers first reported a position in CBRE Group in Q3 2025 and held it in 2 quarters.
PharVision Advisers's CBRE Group position peaked at $221K in Q3 2025.
1,074 funds tracked by Wall St. Rank held CBRE Group as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.